Domain Collabs with Chime for New ANTI-CCR8 Antibody

Domain Collabs with Chime for New ANTI-CCR8 Antibody

By, Admin 14 March 2024

Domain Therapeutics and Chime Biologics Have Agreed to Collaborate on Manufacturing to Advance a New ANTI-CCR8 Antibody for Cancer

Immunotherapy

Observation

Domain Therapeutics (""Domain""), a clinical-stage biopharmaceutical company specializing in immuno-oncology treatments targeting G Protein-Coupled Receptors (GPCRs), has entered a partnership with Chime Biologics, a leading Contract Development and Manufacturing Organization (CDMO) in the biologics sector. The collaboration aims to advance Domain's primary Treg depleting anti-CCR8 antibody candidate, DT-7012, through manufacturing services for potential cancer therapeutics.

Agreement Terms

  • This agreement involves Chime Biologics overseeing stable cell line development (CLD) and manufacturing of the DT-7012 candidate to support clinical trials across strategic regions. 
  • Leveraging Chime Biologics' advanced global modular facility equipped with single-use bioprocessing technology adhering to international cGMP standards, the collaboration seeks to deliver effective therapeutics for cancer patients worldwide.

About DT-7012

  • DT-7012, a novel anti-CCR8 mAb designed to deplete tumor-infiltrating Tregs, pivotal immunosuppressive cells, has demonstrated promising anti-tumor efficacy as a monotherapy. 
  • Its superiority over other clinical-stage CCR8 antibodies positions it as a potential best-in-class candidate, aiming to pioneer GPCR-targeting immunotherapies. 
  • These therapies strive to activate anti-tumor immunity in patients resistant to conventional treatments. 
  • Phase I clinical trials for solid tumors are anticipated to commence in early 2025, followed by mid-2025 trials for cutaneous T-cell lymphoma (CTCL).

Words from Chime Biologics

Dr. Jimmy Wei, President of Chime Biologics, expressed anticipation for the strategic partnership, emphasizing the synergy between Domain's leading antibody candidate and Chime Biologics' expertise in CLD and manufacturing. He envisions the collaboration contributing significantly to advancing DT-7012's development across various cancers.

Words from Domain Therapeutics

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, conveyed excitement about collaborating with Chime Biologics, recognizing their scientific and manufacturing prowess. He emphasized DT-7012's potential to revolutionize cancer treatment by harnessing the immune system's anti-tumor capabilities. Domain prioritizes precision research and innovation, welcoming partnerships with like-minded organizations dedicated to advancing immuno-oncology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!